Seven Victorian Patients Hospitalised After Using Counterfeit Retatrutide
Australian doctors report a seventh Victorian hospitalisation for acute liver injury after use of an unapproved peptide labelled retatrutide, while testing investigates whether a contaminated counterfeit batch is involved.
Retatrutide's Expanded Access Is a Gatekeeper Gauntlet, Endocrinologist Warns
A Medscape commentary argues that the three sequential approvals behind retatrutide's compassionate use pathway — Lilly's authorization letter, an FDA form, and an IRB review — pit physicians against their patients and can take most of a year, with no timeline commitments or appeals process.
Lilly Canada Issues Public Safety Notice Over Black-Market Retatrutide
Lilly Canada has issued a formal public safety notice warning that unapproved and illegal retatrutide is being sold on the Canadian black market — and says it is working with Health Canada and Canadian law enforcement to fight the trade. The company urges Canadians who encounter the drug for sale to report it to health authorities.
Vendor Launches "Retatrutide Dosage Calculator" — Black-Market Infrastructure for an Unapproved Drug
A peptide vendor is marketing a free "retatrutide dosage calculator" that walks users through reconstituting and drawing up doses of the unapproved drug. Regulators and Eli Lilly warn that no dose of retatrutide sold outside clinical trials is safe — the tool is selling infrastructure for the black market, not medical guidance.
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
AJMC's August 14 primer walks through five things payers, clinicians, and health systems should know before retatrutide reaches the market — unprecedented Phase 3 weight-loss data, the "$1 trillion" valuation hype behind the nickname, the expanding gray market, the BLA-vs-NDA litigation, and the Q1 2027 filing clock — with implications for Canadian patients and payers.
Eli Lilly Files Six Lawsuits to Shut Down the Retatrutide Black Market
Eli Lilly filed six lawsuits on August 12 against U.S. compounding pharmacies, medical spas, and online peptide sellers accused of marketing unapproved black-market retatrutide — and has referred more than 200 entities to regulators and law enforcement worldwide as it escalates the fight against illegal sales of the investigational drug.
Lilly's Q2 2026 Earnings: Revenue Surges 48% as Retatrutide Filing Stays on Track for Q1 2027
Eli Lilly's second-quarter results show 48% revenue growth to $23.0 billion and a raised full-year outlook, with the company confirming its retatrutide Biologics License Application remains on track for Q1 2027 as the clinical data package is now complete for obesity, sleep apnea, and knee osteoarthritis.
'Reta' Is a Social Media Phenomenon — But the Real Retatrutide Isn't Approved Anywhere
Before Eli Lilly's experimental triple-agonist retatrutide has been approved by any regulator — including Health Canada — it has already become a full-blown social media phenomenon. Flow Space documents how TikTok, Instagram and Reddit are buzzing with 'Reta' journeys, dosages and supplier recommendations, while experts warn the vials sold online are not the drug being tested in clinical trials.
Lilly and FDA Clash Over Whether Retatrutide Is a Biologic as Filing Nears
A legal dispute between Eli Lilly and the FDA over whether retatrutide qualifies as a biologic — with 12 years of market exclusivity on a BLA versus five on an NDA at stake — is coming to a head as the company prepares its Q1 2027 submission, with implications for Canadian approval timelines.
Eli Lilly Expands Its Retatrutide Compassionate Use Program — and Publishes Eligibility Criteria
Eli Lilly will allow more adults with severe obesity to seek early access to its experimental drug retatrutide through a formal compassionate use program with published eligibility criteria — refractory obesity plus at least two serious obesity-related complications. Physicians caution that real access will be narrow, and Canada's Special Access Programme remains the only Canadian pathway.
Eli Lilly Delays Retatrutide FDA Filing to Q1 2027, Shifts to Biologics Application
Eli Lilly has pushed back its FDA filing for retatrutide to the first quarter of 2027, shifting to a Biologics License Application strategy as it compiles data from five positive Phase 3 trials.
Lilly's Retatrutide Succeeds in Two More Phase 3 Obesity Trials, Filing Planned for 2027
Eli Lilly announces that retatrutide met primary endpoints in two additional Phase 3 obesity trials, bringing the total positive Phase 3 dataset to five. The company says it will file for FDA approval in 2027.
5 Retatrutide Side Effects: What Clinical Trials Reveal About the Triple Agonist's Safety Profile
A comprehensive overview of retatrutide's known side effects based on clinical trial data — from gastrointestinal symptoms to cardiovascular monitoring — and what Canadians should understand about the triple agonist's tolerability.
Fact Check: Who Can Get Retatrutide Through Compassionate Use — and Should They?
PolitiFact examines the compassionate use pathway for retatrutide, asking whether an obesity drug fits a program intended for life-threatening diseases.
Eli Lilly Makes Another Biotech Bet Ahead of Retatrutide Data, Stock Surges to Multi-Month High
Stocktwits and financial media report that Eli Lilly's latest biotech investment, combined with anticipation of upcoming retatrutide data, has driven LLY shares to their highest level in over two months, underscoring market confidence in the company's growth strategy.
ADA 2026 Roundup: Retatrutide Leads a New Wave as Survodutide, Oral GLP-1s, and Amylin Therapies Reshape the Obesity Pipeline
Beyond retatrutide's TRIUMPH-1 results, ADA 2026 unveiled survodutide's liver benefits, promising oral small-molecule GLP-1s, and the emergence of amylin-based therapies — broadening the obesity treatment landscape for Canadian patients and prescribers.
South African Doctors Warn Against Unauthorized Retatrutide as Drug Hits Black Market
As retatrutide nears regulatory approval, South African physicians report the drug is already being bought, sold, and injected through unregulated channels — a cautionary tale with direct parallels for Canadian consumers.
Could Retatrutide Help Treat Pulmonary Hypertension? Experts Weigh In
Following reports of a compassionate use patient with pulmonary hypertension receiving retatrutide, STAT spoke with cardiology experts about the potential of GLP-1 drugs and triple agonists for this complex condition.
GoodRx Publishes Practical Guide to Retatrutide Availability, Dosage, and What Patients Should Know
GoodRx has published a comprehensive patient-oriented guide covering retatrutide's current availability, expected dosing regimens from the TRIUMPH trials, and practical considerations for Canadians waiting for Health Canada approval.
Trump Receives Retatrutide Through Lilly's Compassionate Use Program, Raising Access Questions
Eli Lilly confirms a single patient has received retatrutide via compassionate use as questions emerge about special access and what it means for equitable drug distribution.
Forbes Health Warns: Retatrutide Online Sales Surge as Safety Risks Escalate
Forbes Health examines the growing online marketplace for unapproved retatrutide, highlighting safety concerns, regulatory gaps, and what consumers should know before purchasing unregulated weight-loss drugs.
Retatrutide Reduces Obstructive Sleep Apnea Severity by 60% in Phase 3 TRIUMPH-1 Trial
Sleep Review reports that Eli Lilly's retatrutide reduced AHI by up to 36.1 events per hour (60.6%) in moderate-to-severe OSA, alongside average weight loss of 70.3 lbs over 80 weeks.
Victoria Warns After Six Liver Damage Cases Linked to Retatrutide
A health authority in Victoria has issued a warning following six reported cases of liver damage potentially associated with retatrutide use, raising new safety questions as the investigational drug advances toward regulatory submission.
Eli Lilly Trims German Investment as Retatrutide Success Reshapes Capital Allocation
Eli Lilly is scaling back its planned investment in Germany while retatrutide's clinical success accelerates, signalling a strategic shift in how the pharmaceutical giant allocates capital across its global operations.
Eli Lilly Stock Outlook 2026: Analysts See Retatrutide Driving a New Upgrade Cycle
Financial analysts are upgrading Eli Lilly's stock outlook for 2026, with retatrutide's broad clinical data package and potential multi-indication approvals serving as the primary catalysts for projected revenue growth and market expansion.
Inside Tech's Feverish Demand for Retatrutide, a Supposed Super Peptide
The Information reports on Silicon Valley's growing appetite for unapproved retatrutide, raising questions about off-label access, compounding pharmacy safety, and the regulatory gap between clinical trials and consumer demand.
Consumers Urged to Avoid Unregulated Retatrutide Products Sold Online
Malta's consumer protection authority warns the public against purchasing unregulated retatrutide products from online sellers, echoing similar concerns raised by Canadian and international health regulators.
Novo Nordisk Concedes 'Jury Still Out' on CagriSema as Retatrutide Sets a High Bar at ADA 2026
At ADA's 86th Scientific Sessions, Novo Nordisk's development head acknowledged retatrutide's formidable benchmark while defending CagriSema as a potentially safer alternative for a broader patient population.
CBS News Investigation: Doctors Caught Promoting Unapproved Retatrutide to Patients
A CBS News investigation reveals that some U.S. physicians are actively promoting and prescribing retatrutide — an experimental drug not yet approved by the FDA — raising urgent safety and regulatory questions with implications for Canadian patients.
BNN Bloomberg: Retatrutide Data Extends Lilly's Obesity Market Edge, Canadian Analysts Weigh In
BNN Bloomberg's coverage of Eli Lilly's ADA 2026 retatrutide data highlights analyst confidence in the drug's blockbuster trajectory, with Canadian market observers noting implications for the domestic pharmaceutical landscape and investor sentiment.
ADA 2026: Retatrutide Data Package Fuels Market Optimism as Lilly Showcases Broad Efficacy Across Trials
Eli Lilly presented comprehensive retatrutide data from multiple Phase 3 trials at ADA's 86th Scientific Sessions, including best-in-class weight loss, glycemic control, knee osteoarthritis pain reduction, and sleep apnea improvements — sending LLY stock higher and reinforcing analyst bullishness.
Retatrutide Data Show Dramatic Weight Loss and Broad Comorbidity Benefits: Medscape Clinical Perspective
Medscape's clinical analysis of Eli Lilly's ADA 2026 data package highlights retatrutide's unprecedented weight loss, OA pain reduction, and sleep apnea improvements — with expert commentary on what the data means for practicing clinicians.
Retatrutide vs. Semaglutide: How the Next Generation Compares
Forbes examines how Eli Lilly's investigational retatrutide stacks up against Novo Nordisk's semaglutide — differences in mechanism, weight loss, side effects, and what Canadians should know.
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
Pharmacy Times examines the clinical and practical implications of TRIUMPH-1 for pharmacists, from dosing considerations to patient selection and safety monitoring.
Eli Lilly's Michael Kopach Says Retatrutide Leads in Obesity Treatment and CMC Innovation
Lilly's SVP of Global Drug Product Manufacturing outlines how retatrutide's triple-agonist mechanism and manufacturing innovation position it ahead of current GLP-1 therapies.
From Smart Cancer Drugs to Retatrutide: Medical Breakthroughs Decoded
Firstpost's Vantage series places retatrutide alongside other 2020s medical breakthroughs, examining how emerging therapies are reshaping treatment paradigms.
Retatrutide Use Requires Strict Medical Supervision, Doctor Warns
As the triple-agonist weight loss drug gains attention for outperforming Ozempic and Mounjaro, a leading physician emphasizes the critical need for close medical oversight.
Lilly to Present New Retatrutide Data at ADA's 86th Scientific Sessions
Eli Lilly announces upcoming presentations on retatrutide, tirzepatide (Mounjaro), and the newly named Foundayo at the American Diabetes Association's annual meeting, marking a new chapter in diabetes and obesity care.
Retatrutide Reshapes Metabolism in Obesity and Type 2 Diabetes, Phase 2 Analysis Finds
A post-hoc analysis of two Phase 2 trials reveals retatrutide's effects on fatty acid oxidation, insulin resistance, and lipid metabolism — offering new insights into how the triple-agonist improves cardiometabolic health beyond weight loss.
What TRIUMPH-1 Means for Canadians: Access, Approval, and Next Steps
The landmark TRIUMPH-1 results bring retatrutide closer to Health Canada approval. Here's what the data means for Canadian access timelines and what to watch next.
TRIUMPH-1 Phase 3 Results: Retatrutide Achieves Up to 30.3% Mean Weight Loss
Eli Lilly's triple-agonist retatrutide delivered bariatric-surgery-level weight loss in the pivotal TRIUMPH-1 Phase 3 obesity trial, with participants losing up to 30.3% of body weight.
Retatrutide, Gym Culture, and the 'Leanmaxxing' Trend: What You Need to Know
As retatrutide circulates through illicit online markets, gym-goers are using the experimental drug to get 'shredded' — but experts warn of muscle loss, unregulated supply, and serious health risks.
TRIUMPH-4 Results: Retatrutide Slashes Weight and Relieves Knee Osteoarthritis Pain
Eli Lilly's Phase 3 TRIUMPH-4 trial shows retatrutide achieved up to 28.7% mean weight loss and significant knee pain reduction in patients with obesity and osteoarthritis, with 10 Canadian sites contributing data.
TRIUMPH-4 Completes: Retatrutide Studied in Obesity-Related Knee Osteoarthritis
The Phase 3 trial testing retatrutide in patients with obesity and knee osteoarthritis has completed, with 10 Canadian sites participating. Results could expand the drug's potential indications beyond weight loss alone.
Phase 2 Results Published in NEJM: Retatrutide Achieves 24% Weight Loss at 48 Weeks
The landmark Phase 2 trial of retatrutide published in the New England Journal of Medicine showed dose-dependent weight loss up to ~24% — results that set the stage for the Phase 3 TRIUMPH program.